key: cord-0790300-gm6lznd3
authors: Verhoeven, Frank; Lepiller, Quentin; Hecquet, Sophie; Prati, Clément; Wendling, Daniel
title: SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response
date: 2021-09-02
journal: Joint Bone Spine
DOI: 10.1016/j.jbspin.2021.105258
sha: 4aaeeb0e5aaa875efeca7fe0d36835859e89287d
doc_id: 790300
cord_uid: gm6lznd3

nan

Frank Verhoeven 1, 2, Quentin Lepiller 3 , Sophie Hecquet 1 Clément Prati 1, 2 This is the first report of SARS-CoV2 infection after a well conducted vaccination in a patient treated with rituximab. Impairment of immunogenicity mRNA vaccine was also showed but this is the first case report of SARS-CoV2 infection after an mRNA vaccine (1). Rituximab is known to be associated with more severe SARS CoV-2 (2, 3). Moreover, recents findings suggested that the seroconversion is delayed by the treatment with rituximab secondary to the inhibition of the humoral response to SARS-CoV-2 infection by decreasing CD19 + IgG + (4) (5) . This delay in the seroconversion is present in our case and this is in line with hypothesis of Schulze-Koops et al. Than, Benucci et al. recommended that rituximab retreatment regimen at B cell recovery rather than fixed retreatment schedule might be safer. In our case, the total IgG level was at a satisfactory level for a new infusion. Finally, the serological response to the vaccination was poor. This element is of particular interest because it is the first case report showing a poor response to the SARS-CoV-2 ARN vaccine in a patient treated with rituximab.

The lower vaccine response in Rituximab-treated patients was known for pneumococcal and influenza virus vaccine (6) . Moreover, these elements can serve as a basis for reflection on the vaccination strategy in these patients. A third dose seems to be essential and the delay after the last treatment must be taken into account. It could be discussed to propose vaccination preferably at least 4 months after the last course of rituximab to optimize the vaccination strategy in these patients. The results of large cohorts will provide more answers to these questions.

Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab

Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al. Ann Rheum Dis

Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis

Chronology of events. PCR: polymerase chain reaction